To the full analysis
Buyback calculator for Astellas Pharma
Astellas Pharma stock: key metrics
4503.TAstellas Pharma had an operating margin of 19.6% and a return on invested capital (ROIC) of 14.8% in fiscal 2026.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2007 | 69.1% | 20.7% | 14.3% |
| 2008 | 71.3% | 28.4% | 18.2% |
| 2009 | 72.6% | 25.9% | 17.7% |
| 2010 | 70.3% | 19.1% | 12.5% |
| 2011 | 69.0% | 12.5% | 7.1% |
| 2012 | 67.1% | 13.6% | 8.1% |
| 2013 | 67.8% | 15.3% | 8.2% |
| 2014 | 71.0% | 16.2% | 8.0% |
| 2015 | 73.3% | 17.3% | 10.9% |
| 2016 | 75.6% | 19.6% | 14.1% |
| 2017 | 75.6% | 21.1% | 16.7% |
| 2018 | 77.4% | 20.9% | 12.7% |
| 2019 | 77.6% | 21.4% | 17.0% |
| 2020 | 78.7% | 21.5% | 15.0% |
| 2021 | 80.3% | 20.1% | 9.7% |
| 2022 | 80.5% | 17.0% | 9.6% |
| 2023 | 81.0% | 18.8% | 6.5% |
| 2024 | 81.8% | 11.1% | 1.1% |
| 2025 | 81.7% | 13.4% | 2.7% |
| 2026 | 74.6% | 19.6% | 13.6% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2007 | 11.9% | 20.2% | 9.2% |
| 2008 | 16.0% | 31.7% | 12.7% |
| 2009 | 16.6% | 30.4% | 13.1% |
| 2010 | 11.6% | 24.0% | 9.0% |
| 2011 | 6.6% | 11.4% | 5.1% |
| 2012 | 7.7% | 10.3% | 5.6% |
| 2013 | 7.8% | 13.5% | 5.3% |
| 2014 | 7.2% | 16.4% | 5.5% |
| 2015 | 10.3% | 17.2% | 7.6% |
| 2016 | 15.4% | 21.8% | 10.8% |
| 2017 | 17.2% | 23.4% | 12.1% |
| 2018 | 13.0% | 21.9% | 8.9% |
| 2019 | 17.7% | 26.5% | 11.7% |
| 2020 | 15.2% | 19.1% | 8.4% |
| 2021 | 8.7% | 15.3% | 5.3% |
| 2022 | 8.5% | 12.9% | 5.3% |
| 2023 | 6.5% | 15.8% | 4.0% |
| 2024 | 1.1% | 6.8% | 0.5% |
| 2025 | 3.4% | 11.3% | 1.5% |
| 2026 | 15.9% | 14.8% | 8.2% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 13 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ¥159.70)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 2 Jan 2026)
- Valuation signal Fairly valued since 8 Nov 2026, previously Undervalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.